<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="835">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150288</url>
  </required_header>
  <id_info>
    <org_study_id>1806INF- DACH</org_study_id>
    <nct_id>NCT05150288</nct_id>
  </id_info>
  <brief_title>Human Milk Oligosaccharides (HMOs) Post-market Study on Infants (NEHMO)</brief_title>
  <acronym>NeHMO DACH</acronym>
  <official_title>Growth and Feeding Tolerance of Infants Consuming a Formula Supplemented With Human Milk Oligosaccharides (HMOs): An Uncontrolled, Open-label, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Waldkrankenhaus Protestant Hospital, Spandau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinderarztpraxis Köllges, Mossakowski und Meyer-Krott, Mönchengladbach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gemeinschaftspraxis Kinder- und Jugendpraxis Dr. Stepan Dreher und Tina Hübler, Geldern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinder- und Jugendarzt Dr. Umpfenbach und Dr. Lorenz, Viersen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinder- und Jugendärztliche Gemeinschaftspraxis Bedikian &amp; Bouikidis, Oberhausen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinderarztpraxis Dr. Zakarian, Düsseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Facharztpraxis für Kinder- und Jugendmedizin Dr. Aulinger, Burglengenfeld</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zentrum für Kinder- und Jugendgesundheit Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinder- und Jugendarztpraxis Schwabach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Praxis Dr. Klee, Bürstadt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Facharzt für Säuglings-, Kinder- und Jugendmedizin, Bremen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Praxis Al-Radhi, Ehingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinder und Jugendarztpraxis Dr. Maier, Leinfelden-Echterdingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinder- und Jugendarztpraxis Dr. Kröckel, Dr. Ciesla, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Facharzt für Kinder- und Jugendheilkunde Dr. Faustmann, Oberwart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nestlé Research, Société des Produits Nestlé S.A., Lausanne, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Global Medical Affairs, Société des Produits Nestlé S.A., Vevey, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human milk oligosaccharides (HMOs) represent the third largest solid component of breast&#xD;
      milk. Technology advancements made it possible to supplement infant formulas with HMOs (2'FL,&#xD;
      LNnT). Two published RCTs have demonstrated that infant formulas supplemented with 2'FL or&#xD;
      2'FL+LNnT are safe, well-tolerated, support normal grow, and may support healthy GI function&#xD;
      and confer immune benefits. The performance of HMOs-supplemented formulas assessed in a&#xD;
      real-world setting is complementary to previously conducted RCTs conducted in highly&#xD;
      controlled clinical settings. Main objectives will be to monitor the safety &amp; tolerance of&#xD;
      HMOs-supplemented formulas in larger and diverse infant populations; to assess the&#xD;
      performance of HMOs-supplemented formulas in mixed-fed infants, a population that was not&#xD;
      studied in previous RCTs but likely represents a relatively common feeding regimen. Finally,&#xD;
      considering the potential health/immune benefits of HMOs, it is also important explore the&#xD;
      incidences of illnesses (i.e., respiratory illnesses, GI illnesses, and fever) associated&#xD;
      with consuming HMOs-supplemented formulas and compare with breastfed infants data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      The main objective of this study is to document the growth and feeding tolerance of healthy&#xD;
      term infants consuming an infant formula supplemented with HMOs for 8 weeks (56 days), in a&#xD;
      real-world setting.&#xD;
&#xD;
      Main endpoints:&#xD;
&#xD;
        1. Growth documented via monitoring the anthropometric parameters including weight, length,&#xD;
           head circumference, BMI and their corresponding z-scores (i.e., z-scores for&#xD;
           weight-for-age, length-for-age, weight-for-length, head circumference-for-age, and&#xD;
           BMI-for-age) calculated using the 2006 WHO Growth Standards&#xD;
&#xD;
        2. Feeding tolerance assessed via monitoring parent-reported overall GI symptom burden&#xD;
           measured by the Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score&#xD;
           (13-item summary score)&#xD;
&#xD;
      Additional objectives:&#xD;
&#xD;
      To describe the following outcomes in infants fed an infant formula supplemented with HMOs:&#xD;
&#xD;
        1. Formula acceptability&#xD;
&#xD;
        2. Despite there are no expected safety concerns, standard Adverse Events (AEs) monitoring&#xD;
           will be implemented during the study&#xD;
&#xD;
      Additional endpoints:&#xD;
&#xD;
        1. Formula acceptability assessed by the Study Formula Satisfaction Questionnaire&#xD;
&#xD;
        2. Reported AEs and Serious Adverse Events (SAEs) including type, incidence, severity,&#xD;
           seriousness and relation to study formula consumption as well as concomitant medications&#xD;
           and non-pharmacological treatments.&#xD;
&#xD;
             -  Select morbidities of interest (i.e., respiratory illnesses, GI illnesses, and&#xD;
                fever) will be collected as part of AE reporting and specific corresponding AE&#xD;
                guidance forms will be used to standardize reporting of such AEs&#xD;
&#xD;
      Trial design:&#xD;
&#xD;
      Uncontrolled, single arm, open-label, prospective study in infants (enrolled at postnatal age&#xD;
      7 days to 2 months) fed the study formula for 8 weeks (56 days)&#xD;
&#xD;
      A group of exclusively breastfed infants (BF) will serve as a reference group in parallel to&#xD;
      the study arm. For the BF group, Infants must have been exclusively consuming breast milk&#xD;
      since birth, and their parent(s) must have made the decision to continue exclusively&#xD;
      breastfeeding until at least 4 month of age&#xD;
&#xD;
      Trial population:&#xD;
&#xD;
      Healthy, male and female, term infants, 7 days postnatal age to 2 months of age at the&#xD;
      enrollment&#xD;
&#xD;
      Treatment duration:&#xD;
&#xD;
      Total study participation/intervention up to approximately 8 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Actual">July 24, 2020</completion_date>
  <primary_completion_date type="Actual">July 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>World Health Organization (WHO) based weight-for-age z-scores</measure>
    <time_frame>8 weeks (study end)</time_frame>
    <description>Weight-for-age z-scores using WHO growth standards</description>
  </primary_outcome>
  <primary_outcome>
    <measure>World Health Organization (WHO) based length-for-age z-scores</measure>
    <time_frame>8 weeks (study end)</time_frame>
    <description>Length-for-age z-scores using WHO growth standards</description>
  </primary_outcome>
  <primary_outcome>
    <measure>World Health Organization (WHO) head-circumference-for-age z-scores</measure>
    <time_frame>8 weeks (study end)</time_frame>
    <description>head-circumference-for-age z-scores using WHO growth standards</description>
  </primary_outcome>
  <primary_outcome>
    <measure>World Health Organization (WHO) based body-mass-index (BMI)-for-age z-scores</measure>
    <time_frame>8 weeks (study end)</time_frame>
    <description>Weight and height will be combined to calculate BMI in kg/m^2, then BMI-for-age z-scores will be derived using WHO growth standards</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feeding tolerance</measure>
    <time_frame>4 weeks (study midpoint)</time_frame>
    <description>The Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score will be used to assess GI distress. This is a validated 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress. A composite IGSQ score is derived from summing the individual scores with a possible range of 13 to 65 where higher values indicate greater GI distress and values ≤23 indicate no digestive distress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feeding tolerance</measure>
    <time_frame>8 weeks (study end)</time_frame>
    <description>The Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score will be used to assess GI distress. This is a validated 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress. A composite IGSQ score is derived from summing the individual scores with a possible range of 13 to 65 where higher values indicate greater GI distress and values ≤23 indicate no digestive distress</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Formula acceptability</measure>
    <time_frame>4 weeks (study midpoint), 8 weeks (study end)</time_frame>
    <description>Study Formula Satisfaction Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard adverse events (AEs) reporting for safety assessment</measure>
    <time_frame>From the time the informed consent form has been signed at enrollment infant age less than 7 days to 2 months through the 8 weeks of intervention</time_frame>
    <description>Reported adverse events (AEs) and Serious Adverse Events (SAEs) include type, incidence, severity, seriousness and relation to feeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>8 weeks (study end)</time_frame>
    <description>Weight measurements in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length</measure>
    <time_frame>8 weeks (study end)</time_frame>
    <description>Length measurements in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head circumference</measure>
    <time_frame>8 weeks (study end)</time_frame>
    <description>Head circumference measurements in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body-mass-index (BMI)</measure>
    <time_frame>8 weeks (study end)</time_frame>
    <description>Weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Growth</condition>
  <condition>Tolerance</condition>
  <condition>Adverse Event</condition>
  <condition>Disorder of Intestine</condition>
  <condition>Formula Satisfaction</condition>
  <arm_group>
    <arm_group_label>Formula-fed infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants fed exclusively with experimental formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mixed-fed infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants receiving breastmilk and experimental formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast-fed infants</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Reference group of exclusively breastfed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HMO-supplemented infant formula</intervention_name>
    <description>Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides</description>
    <arm_group_label>Formula-fed infants</arm_group_label>
    <arm_group_label>Mixed-fed infants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evidence of personally signed and dated informed consent document indicating that the&#xD;
             infant's parent(s) have been informed of all pertinent aspects of the study&#xD;
&#xD;
          -  Parent(s) are willing and able to fulfill the requirements of the study protocol&#xD;
&#xD;
          -  Healthy full term (37-42 weeks gestation) infant&#xD;
&#xD;
          -  Be between post-natal age (Date of Birth = Day 0) 7 days to 2 months&#xD;
&#xD;
          -  Parent(s) must have independently elected, before enrollment, to formula feed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known intolerance/allergy to cow's milk (formula-fed group only)&#xD;
&#xD;
          -  systemic disorders (cardiac, respiratory, endocrinological, hematologic,&#xD;
             gastointestinal, or other)&#xD;
&#xD;
          -  conditions requireing infant feedings other than those specified in the protocol&#xD;
&#xD;
          -  Infants must have been exclusively consuming breast milk since birth, and their&#xD;
             parent(s) must have made the decision to continue exclusively breastfeeding until at&#xD;
             least 4 month of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Facharzt für Kinder- und Jugendheilkunde</name>
      <address>
        <city>Oberwart</city>
        <zip>7400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Waldkrankenhaus Spandau</name>
      <address>
        <city>Berlin-Spandau</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinder- und Jugensarztpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>12689</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Säuglings-, Kinder- und Jugendmedizin</name>
      <address>
        <city>Bremen</city>
        <zip>28211</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharztpraxis für Kinder- und Jugendmedizin</name>
      <address>
        <city>Burglengenfeld</city>
        <zip>93133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Klee</name>
      <address>
        <city>Bürstadt</city>
        <zip>68642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderarztpraxis</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Al-Radhi</name>
      <address>
        <city>Ehingen</city>
        <zip>89584</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Kinder- und Jugendarztpraxis</name>
      <address>
        <city>Geldern</city>
        <zip>47608</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinder und Jugendarztpraxis</name>
      <address>
        <city>Leinfelden-Echterdingen</city>
        <zip>70771</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderarztpraxis Köllges</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinder- und Jugendärztliche Gemeinschaftspraxis</name>
      <address>
        <city>Oberhausen</city>
        <zip>46145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Kinder- und Jugendgesundheit</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinder- und Jugendarztpraxis</name>
      <address>
        <city>Schwabach</city>
        <zip>91126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinder- und Jugendarzt</name>
      <address>
        <city>Viersen</city>
        <zip>41751</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nestlé Research, Société des Produits Nestlé S.A.</name>
      <address>
        <city>Lausanne</city>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Medical Affairs, Société des Produits Nestlé</name>
      <address>
        <city>Vevey</city>
        <zip>1800</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Storm HM, Shepard J, Czerkies LM, Kineman B, Cohen SS, Reichert H, Carvalho R. 2'-Fucosyllactose Is Well Tolerated in a 100% Whey, Partially Hydrolyzed Infant Formula With Bifidobacterium lactis: A Randomized Controlled Trial. Glob Pediatr Health. 2019 Mar 15;6:2333794X19833995. doi: 10.1177/2333794X19833995. eCollection 2019.</citation>
    <PMID>30906817</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth</keyword>
  <keyword>Tolerance</keyword>
  <keyword>Adverse Event</keyword>
  <keyword>Gastrointestinal tolerance</keyword>
  <keyword>Infant formula</keyword>
  <keyword>Human milk oligosaccharides</keyword>
  <keyword>2'-fucosyllactose</keyword>
  <keyword>Lacto-N-neotetraose</keyword>
  <keyword>Real-world</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

